Project Banksia will see the delivery of a new world-class biotech manufacturing facility, built in Tullamarine, Australia.<br /> <br /> The state-of-the-art facility will use innovative cell-based technology to produce influenza vaccines for use in both influenza pandemics and seasonal vaccination programs – and will be the only cell-based influenza vaccine manufacturing facility in the Southern Hemisphere.<br /> <br /> The centre will include PC2 and PC3 laboratories, black and clean utilities, warehousing, administration offices, an onsite cafeteria and quality control facilities.